-
Baiji Shenzhou BTK inhibitor Zebutini new adaptive disease listing application was accepted by the FDA
Time of Update: 2021-02-24
On February 17, Baiji Shenzhou announced that the U.S. FDA had accepted a new application (SNDA) for the treatment of patients with Fahrenheit globulinemia (WM), with the PDUFA dated October 18, 2021.
-
Pfizer's submission of the latest stability data for the new crown vaccine is expected to increase storage/shipping flexibility
Time of Update: 2021-02-24
to the FDA includes stability data for different batches produced during the development of the new crown vaccine over the past nine months.
PFIZER AND BIONTECH SUBMIT COVID-19 VACCINE STABILITY AT STANDARD FREEZER TO TO U.S. FDA.
-
Heavy! Four departments issued a paper to end the Chinese medicine formula particle pilot
Time of Update: 2021-02-24
5. The provincial drug supervision and administration departments, together with the provincial Chinese medicine authorities, shall formulate corresponding management rules in the light of the relevant provisions of the national and local industrial policies and the actual clinical needs, adhere to the main position of Chinese medicine tablets, and ensure the smooth and orderly development and rational use of Chinese medicine formula particles within the jurisdiction.
-
Guangxi Medical Complex: Unified procurement of pharmaceutical supplies unified payment
Time of Update: 2021-02-24
Unified procurement unified payment, the basic medical device procurement model changes "notice" first clearly, the current measures referred to as the medical association including but not limited to urban medical groups, county medical and health community (hereinafter referred to as county medical community), three-two medical associations, specialized alliances and telemedicanic collaboration network.
-
A new generation of antibody-coupled drugs is eligible for FDA priority review
Time of Update: 2021-02-24
if BCG is ineffective or if the patient needs to receive BCG for a long time, the recommended treatment is a complete removal of the bladder.
Vicineum is a next-generation ADC drug developed using Sesen Bio's proprietary targeted protein therapy platform.
-
National mining press the accelerator key, where does generic drugs go from here?
Time of Update: 2021-02-24
Medicine Network February 20th, before the New Year, the National Health Insurance Administration to the people of the country sent a new annual gift. La Month 28 (February 8), the fourth batch of nat
-
Drug enterprise risk warning issued 33 pharmaceutical companies on the list!
Time of Update: 2021-02-24
2, Shandong Weizhi Encycloddic Pharmaceutical Co., Ltd. the company produced hydrochloric acid Lidokain injection, "check" item "visible foreign body" does not meet the standard provisions, Shandong Provincial Drug Administration issued a decision on administrative punishment, fined about 495,000 yuan.
-
The State Drug Administration revised the six-flavored yellow preparation instruction manual
Time of Update: 2021-02-24
Annex Annex 2 Revised requirements for over-the-counter prescription drugs for six-flavored yellow preparations Should include: Monitoring data show that six-flavored yellow preparations have diarrhea, abdominal pain, bloating, nausea, vomiting, gastrointestinal discomfort, loss of appetite, constipation, itching, rash, headache, palpitations, allergies and other adverse reactions reported.
-
FDA accelerates approval of innovative PI3K inhibitors to treat lymphoma
Time of Update: 2021-02-24
in patients with marginal lymphoma (MZL), Ukoniq achieved an objective remission rate (ORR) of 49%, including a full remission rate of 16%, and the medium remission duration (DOR) had not yet been achieved.
-
Jiangsu Province not listed products without national medical insurance drug code will not be able to declare sunshine procurement
Time of Update: 2021-02-24
april 1, 2021, the national medical insurance drug classification and code published by the provincial platform network products will be displayed in the drug settlement trading system for the transaction subject to be compared.
-
Health Care Commission: 18 new confirmed cases are imported from abroad
Time of Update: 2021-02-24
From 0:24 p.m. on February 18, 31 provinces (autonomous regions, municipalities directly under the Central Government) and the Xinjiang Production and Construction Corps reported 10 new confirmed cases, all of which were imported from abroad (7 in Shanghai, 2 in Tianjin and 1 in Hunan); 46 new cases were cured and discharged from hospital on the same day, 406 close contacts were released from medical observation, and 2 cases of severe illness were reduced from the previous day.
-
FDA approves new drug extension adaptation for Parkinson's disease
Time of Update: 2021-02-24
from two key, placebo-controlled Phase 3 clinical trials, Gocovri's treatment significantly reduced "off-period" time and movement disorders.
is now the only drug approved for treatment of Parkinson's disease 'off period' and complications of movement disorders.
-
7618 pharmaceutical companies were named! If you don't do it again, the winning product will be removed from the network...
Time of Update: 2021-02-24
Pharmaceutical Network February 8 - Zhejiang Pharmaceutical Procurement Center recently issued a notice, named 7618 enterprises, urging the pharmaceutical enterprises as soon as possible to submit the
-
These 13 new drugs are on: Hengrui, Haizheng, and Huang...
Time of Update: 2021-02-24
China's public medical institutions terminal blood lipid drug sales source: Minet China's public medical institutions terminal competition pattern Haize mebu tablets are the first Haizheng Pharmaceuticals to declare the listing of a new class of drugs, its research and development investment has reached 280 million yuan, some brokerages predict that its approval is expected to become a billion-class heavy varieties.
-
3 days 3 license-in super 2.8 billion traditional pharmaceutical giant innovation transformation into the era of rapid growth
Time of Update: 2021-02-24
February 16, Qilu Pharmaceuticals signed a cooperation agreement with Cend Therapeutics, a U.S. biotech company, to obtain exclusive rights to Cend's new cancer drug in Greater China for up to $235 million.
-
How to solve the primary problem of medical reform? The maximum price is the key!
Time of Update: 2021-02-24
Next, led by the Health Insurance Bureau to monitor drugs, for example, after a year of monitoring, drug A most hospital procurement price of 8 yuan / branch, the market supply is adequate, the operation of enterprises is good, although there are individual enterprises have a loss, because of the enterprise's low level of science and technology, poor management capacity, at the same time, found that some hospitals still have doctors to take kickbacks.
-
The application for the listing of regenerant biology Terripley single anti-new anti-adhesive disease was accepted
Time of Update: 2021-02-24
On February 18, Junshi Bio announced that the company had received a "notice of acceptance" approved by the State Drug Administration, and that the new adaptation application for Ripley monoantithermal combination chemotherapy for advanced first-line relapsed metastatic nasopharyngeal cancer that had not received systematic treatment was accepted.
-
The first in the country! Anhui introduced a DIP guidance program for 7 cities pilot
Time of Update: 2021-02-24
Medical Network February 9, 2021 - February 1, 2021, Anhui Provincial Health Security Bureau, Anhui Provincial Health And Health Committee, Anhui Provincial Finance Department on the issuance of "Anhu
-
Supplies overhaul the Municipal Commission for Discipline Inspection supervision assigned to 12 groups of full-process supervision
Time of Update: 2021-02-24
For pharmaceutical enterprises rated as "particularly serious", in addition to warning and warning of risks, the enterprise shall be restricted or suspended all drugs and medical supplies hanging network, bidding or distribution qualifications, restrictions or suspension period according to the pharmaceutical enterprise credit repair behavior and results of timely adjustment.
-
2020 Drug Quality Announcement Large Inventory
Time of Update: 2021-02-24
The chart above shows the ranking of more than 6 batches (including 6 batches) the top five non-conforming test items for Chinese herbal medicine/Chinese medicine tablets are characteristics (365 batches), content determination (236 batches), identification (88 batches), total ash (62 batches), inspection (39 batches).
